U.S. Markets open in 5 hrs 12 mins

TG Therapeutics, Inc. (TGTX)

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Add to watchlist
11.55-0.25 (-2.12%)
At close: 4:00PM EDT
People also watch
FOLDESPRAUPHPTCTOMER

TG Therapeutics, Inc.

2 Gansevoort Street
9th Floor
New York, NY 10014
United States
212-554-4484
http://www.tgtherapeutics.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees63

Key Executives

NameTitlePayExercisedAge
Mr. Michael S. Weiss Esq., J.D.Exec. Chairman, Chief Exec. Officer and Pres651kN/A51
Mr. Sean A. Power CPAChief Financial Officer, Corp. Sec. and Treasurer372.86kN/A35
Jenna BoscoDirector of Investor RelationsN/AN/AN/A
Dr. Robert Niecestro Ph.D.Exec. VP of Clinical and RegulatoryN/AN/A66
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

TG Therapeutics, Inc., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases primarily in the United States. It develops TG-1101 (ublituximab), a chimeric, glycoengineered monoclonal antibody that targets an epitope on the CD20 antigen found on the surface of B-lymphocytes developed to aid in the depletion of circulating B-cells; and TG-1101 in combination with TGR-1202 for relapsed/refractory non-Hodgkin’s lymphoma and chronic lymphocytic leukemia. The company also develops TGR-1202, an orally available phosphoinositide-3-kinase delta inhibitor with nanomolar potency to the delta isoform and high selectivity over the alpha, beta, and gamma isoforms, as well as for hematologic malignancies. In addition, it develops a pre-clinical program to develop interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitors; bromodomain and extra terminal (BET) inhibitor program in the field of hematological malignancies; and anti-PD-L1 and anti-GITR antibody research programs that are in pre-clinical development stage in the field of hematological malignancies. The company has license agreements with LFB Biotechnologies S.A.S, GTC Biotherapeutics, LFB/GTC LLC, and Ildong Pharmaceutical Co. Ltd. for the development and commercialization of TG-1101 (ublituximab); Rhizen Pharmaceuticals, SA for the development and commercialization of TGR-1202; Ligand Pharmaceuticals Incorporated for the development and commercialization of IRAK4 inhibitor technology; Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs; and Jubilant Biosys for the development and commercialization of BET inhibitor program. TG Therapeutics, Inc. is headquartered in New York, New York.

Corporate Governance

TG Therapeutics, Inc.’s ISS Governance QualityScore as of July 1, 2017 is 9. The pillar scores are Audit: 2; Board: 10; Shareholder Rights: 6; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.